Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Sai-Hong Ignatius Ou

Alectinib in ALK -Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial

The Lancet Oncology

Oncology

2016

English

Identification ofBRAFKinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy

English

Gene of the Month: Neuregulin-1 Fusion Positive NSCLC (NRG1+ NSCLC)

Journal of Thoracic Oncology

English

Characterization of 298 Patients With Lung Cancer Harboring MET Exon 14 Skipping Alterations

Journal of Thoracic Oncology

English

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology

English

Carving Out Another Slice of the Pie: Exceptional Response to Single Agent Imatinib in an Asian Female Never-Smoker With Advanced NSCLC and a De-Novo PDGFR-α N848 K Mutation

English

ASCEND-2: A Canary in a Coal Mine for Descending to Second-Line Treatment for ALK-rearranged Non-Small Cell Lung Cancer

Translational Lung Cancer Research

Oncology

2016

English

Dramatic Response to Alectinib in a Lung Cancer Patient With a Novel VKORC1L1-ALK Fusion and an Acquired ALK T1151K Mutation

Lung Cancer: Targets and Therapy

Oncology

2018

English

Factors Associated With Sinus Bradycardia During Crizotinib Treatment: A Retrospective Analysis of Two Large-Scale Multinational Trials (PROFILE 1005 and 1007)

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Sai-Hong Ignatius Ou

Alectinib in ALK -Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial

Identification ofBRAFKinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy

Gene of the Month: Neuregulin-1 Fusion Positive NSCLC (NRG1+ NSCLC)

Characterization of 298 Patients With Lung Cancer Harboring MET Exon 14 Skipping Alterations

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer

The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer

Carving Out Another Slice of the Pie: Exceptional Response to Single Agent Imatinib in an Asian Female Never-Smoker With Advanced NSCLC and a De-Novo PDGFR-α N848 K Mutation

ASCEND-2: A Canary in a Coal Mine for Descending to Second-Line Treatment for ALK-rearranged Non-Small Cell Lung Cancer

Dramatic Response to Alectinib in a Lung Cancer Patient With a Novel VKORC1L1-ALK Fusion and an Acquired ALK T1151K Mutation

Factors Associated With Sinus Bradycardia During Crizotinib Treatment: A Retrospective Analysis of Two Large-Scale Multinational Trials (PROFILE 1005 and 1007)